112 results about "Choroid membrane" patented technology

The invention relates to sustained release implants and to methods for treating eyes, particularly the eyes of mammals having eye disorders or diseases. By using the implants and methods described herein, the delivery of the one or more bioactive agents can be localized at a desired treatment site, particularly the choroid and the retina.

Disclosed herein are compositions and methods for treating ocular diseases, inter alia, diabetic macular edema, age-related macular degeneration (wet form), choroidal neovascularization, diabetic retinopathy, retinal vein occlusion (central or branch), ocular trauma, surgery induced edema, surgery induced neovascularization, cystoid macular edema, ocular ischemia, uveitis, and the like. These diseases or conditions are characterized by changes in the ocular vasculature whether progressive or non-progressive, whether a result of an acute disease or condition, or a chronic disease or condition.

Intravitreal administration of a JNK-inhibitory peptide less than 150 amino acids in length, containing at least one D-amino acid, and having (a) a JNK-inhibitory sequence of at least any of SEQ ID NO: 1 and SEQ ID NO: 2, and (b) a transport sequence of at least any of SEQ ID NO: 3 and SEQ ID NO: 4 suppressed spermidine-induced retinal pigment epithelial damage, tunicamycin-induced photoreceptor cell damage, and laser-induced choroidal neovascularization. Thus, the JNK-inhibitory peptide of the present invention is useful for prophylaxis or therapy of a retinal disease. By the use of this JNK-inhibitory peptide, a drug and a method are provided which are capable of preventing or treating a retinal disease even by topical administration to the eye, and use of the JKN-inhibitory peptide for manufacturing the drug is also provided.

The invention provides an apparatus, a device, and methods for imaging vasculature in a subject as well as an apparatus, a device and methods for treating abnormal vasculature in a subject.

The invention discloses a method and system for segmenting choroidal neovascularization from a fundus OCT image in the technical field of medical image processing. The objective of the invention is tosolve the technical problems of low segmentation accuracy and unclear lesion boundary regions in a choroidal neovascularization segmentation result in the prior art. The method comprises the steps ofcollecting a fundus OCT image containing choroidal neovascularization lesions; constructing a convolutional neural network based on a differential amplification module; training and testing the constructed convolutional neural network based on the differential amplification module; and segmenting choroidal neovascularization from the fundus OCT image by using the trained network. According to theinvention, the VGG16 is used as a coding part of the U-Net network; a differential amplification module is connected after the pooling operation of each convolution block; according to the method, abinary cross entropy loss function and a Dice loss function are used as loss functions to restrain the whole network, so that the segmentation accuracy is high, and a lesion boundary region is clearerand more accurate.

Described herein are liquid formulations which deliver a variety of therapeutic agents, including but not limited to rapamycin, to a subject for an extended period of time; liquid formulations which form a non-dispersed mass when placed in an aqueous medium; nondispersed mass-forming liquid formulations which form a gel or gel-like substance in an aqueous medium; liquid formulations, comprising a therapeutic agent and polymers; and methods for delivering therapeutic agents to a subject for an extended period of time using the liquid formulations. The liquid formulation may be placed in an aqueous medium of a subject, including via intraocular or periocular administration, or placement proximate to a site of a disease or condition to be treated in a subject. A method may be used to administer rapamycin to treat or prevent angiogenesis, choroidal neovascularization, or age-related macular degeneration, or wet age- related macular degeneration.

This invention relates to the expression method of adeno-associated virus-mediated gene in retinal cells. This invention can significantly improve the transfer efficiency and gene expression level of adeno-associated virus-mediated gene in retinal cells by using a combination of different types of adeno-associated virus, and has no toxic or side effect. Experimental results show that at a certain dosage range, replication-competent adenovirus and replication-defective adenovirus can significantly accelerate AAV2-mediated gene expression, and no cell lesion is observed. This invention can be used for gene treatment of ocular fundus diseases, such as retinosis, maculopathy, diabetic retinopathy, uveitis, choroidal neovascularization, optic nerve degeneration and damage.

The invention provides an application of puerarin gel eye drop in preparation of drugs for treating ischemic ocular fundus diseases. The eye drop is prepared from puerarin, EDTA, sodium metabisulfite, borneol, benzalkonium bromide, poloxamer 407, sodium hyaluronate, sodium citrate, citric acid and injection water, an HPLC-UV method is adopted, intraocular pharmacokinetics of rabbits proves that the absorbed doses of 1.2% puerarin gel eye drop in retina and choroid are respectively larger than 70% and 62% in common puerarin eye drop; converted according to specific gravity of aqueous fluid and vitreous body, intraocular puerarin contents satisfy the relation that choroid> retina>aqueous fluid > vitreous body, which indicates that an enough absorbed dose of the puerarin can reach ocular fundus. Observation finds that average drug contents (ng/g) of the 1.2% puerarin gel eye drop on time points of a 1-6 hour puerarin time-concentration curve of rabbit retina and choroid are not lower than contents (ng/g) measured when rabbits effectively induce reinforced ocular fundus blood flow velocity in retina hemodynamics measurement, so that the fact that the puerarin gel eye drop can be used as intravenous puerarin for treating ischemic ocular fundus diseases can be proved.

The present invention provides novel pharmaceutical agents and methods for treating or preventing diseases caused by neovascularization in human choroid (neovascular maculopathy). The present invention provides pharmaceutical compositions and vaccines for treating and/or preventing diseases caused by neovascularization in human choroid (neovascular maculopathy), comprising at least one type each of a peptide comprising an amino acid sequence derived from a VEGFR-1 protein and having an activity of inducing cytotoxic T cells, and a peptide comprising an amino acid sequence derived from a VEGFR-2 protein and having an activity of inducing cytotoxic T cells.

The invention relates to an OCT image-based Alzheimer's disease risk prediction method and system and a medium. The OCT image-based Alzheimer's disease risk prediction method comprises the following steps that a fundus OCT image is input into a trained retina segmentation model to obtain a segmentation mask of a retina region; a fundus OCT image is input into a trained choroid segmentation model to obtain a segmentation mask of a choroid region; the position of a macular central recess is detected; the distance between the upper and lower boundaries of the retina segmentation mask and the choroid segmentation mask at the macular central recess is calculated to obtain the retina thickness and the choroid thickness at the corresponding positions; and the omentum thickness, the choroid thickness and the age and gender information of the person taking the fundus OCT image are input into an optimized multi-index Logistic regression model to obtain the disease risk level of the Alzheimer's disease. The retina and choroid segmentation and thickness measurement are carried out by adopting a Unet network structure, the accuracy is high, a multi-factor disease risk prediction model is constructed, and a more reliable result for predicting the Alzheimer's disease patient can be provided.

Objects of the present invention are to study on the synthesis of a novel pyrrole derivative having a ureido group and an aminocarbonyl group as substituents or a salt thereof, to find a pharmacological effect of the derivative or a salt thereof, and to find a medicinal agent which has a prophylactic and/or therapeutic effect on a retinal disease or the like through oral administration. A compound represented by the general formula (1) or a salt thereof has an inhibitory activity against the production of interleukin-6 and/or an inhibitory effect on choroidal neovascularization, and is therefore useful as a prophylactic and/or therapeutic agent for a disease associated with interleukin-6, an ocular inflammatory disease and/or a retinal disease. In the formula, the ring A represents a benzene ring or the like; R¹ represents a halogen atom, a hydrogen atom, a lower alkyl group or the like; R² represents a halogen atom, a lower alkyl group which may have a substituent, a lower alkenyl group, a lower alkynyl group which may have a substituent, a lower cycloalkyl group, an aryl group, a hydroxy group, a lower alkoxy group which may have a substituent or the like; and n represents 0, 1, 2, 3 or the like.

Described herein are liquid rapamycin formulations. Described herein are methods of treating or preventing diseases or conditions, such as choroidal neovascularization, wet AMD and dry AMD, and preventing transition of dry AMD to wet AMD, using the liquid rapamycin formulations described herein.

The invention provides a choroid layer segmentation method based on ARU-Net. The method comprises the following steps: collecting an OCT choroid image; processing the OCT choroid image to obtain a choroid data set; dividing the choroid data set into a training set, a verification set and a test set, and performing data enhancement on the training set; constructing an ARU-Net model, and training the ARU-Net model by using the training set and the verification set; predicting the test set by using the trained ARU-Net model to obtain a choroidal prediction probability graph; setting a probability threshold, and obtaining a choroid segmentation prediction graph; and obtaining a choroidal layer boundary according to the choroidal segmentation prediction graph. According to the invention, the OCT choroidal image can be automatically segmented to obtain the choroidal layer boundary.

The invention discloses a choroidal OCT image enhancement method and device based on signal reverse compensation. After a choroid image signal acquired by a system is preprocessed, a reverse signal attenuation compensation model is established based on the idea of OCT back scattering signal reverse compensation, the choroid signal is reversely compensated, and the signal-to-noise ratio between a blood vessel and a non-blood vessel tissue is enhanced, so that the defect that the boundary of a choroid blood vessel OCT image is difficult to segment is overcome.